Eiger BioPharmaceuticals, Inc.
EIGR
Rank in Stocks
#36453
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
-79.71%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)
Category
Healthcare
Revenue for Eiger BioPharmaceuticals, Inc. (EIGR)
Revenue in Dec 2023 TTM: $15.77M
According to Eiger BioPharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $15.77M. In 2022 the company made a revenue of $13.48M an increase over the revenue in the year 2021 that was $12.14M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eiger BioPharmaceuticals, Inc. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $15.77M | 0.00% |
| 2023 | $15.77M | 16.98% |
| 2022 | $13.48M | 11.05% |
| 2021 | $12.14M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 79,937.41% |
US
|
|
| $2.23B | 14,025.40% |
US
|
|
| $15.74B | 99,718.22% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 38,074.65% |
NL
|
